<DOC>
	<DOC>NCT00711139</DOC>
	<brief_summary>The purpose of this study is to assess the long-term tolerability and -safety of AFFITOPE AD01 applied during AFFiRiS 001</brief_summary>
	<brief_title>Long-term Safety and Tolerability of AFFITOPE AD01</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Written informed consent signed and dated by the patient or the patient's legal representative and the caregiver Patients having participated in AFFiRiS 001 and received at least 1 vaccination with AFFITOPE AD01 Availability of a partner/caregiver knowing the patient and being able to accompany the patient to the visits. Patients having received no vaccination with AFFITOPE AD01 Contraindication for MRI imaging History of questionable compliance to visit schedule, patients not expected to complete the clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Morbus Alzheimer</keyword>
	<keyword>Alzheimer Vaccine</keyword>
	<keyword>Vaccine</keyword>
	<keyword>AD</keyword>
	<keyword>A-beta immunotherapy</keyword>
</DOC>